STOCK TITAN

Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program To Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Alkermes plc (Nasdaq:ALKS) announced the opening of applications for its Alkermes Inspiration Grants program on May 1, 2023. The program aims to distribute $500,000 in total grants to nonprofit organizations addressing addiction, serious mental illness, and cancer. This marks the seventh year of the program, which evaluates proposals focused on underrepresented populations dealing with challenges such as alcohol dependence, opioid dependence, and certain cancers. Submissions will be accepted until June 1, 2023, with grant recipients selected based on defined criteria. Alkermes emphasizes its commitment to empowering communities and supporting organizations that complement medical care.

Positive
  • Alkermes plans to allocate up to $500,000 in grants to support nonprofit organizations.
  • The program targets significant health challenges faced by underrepresented populations.
Negative
  • None.

DUBLIN / ACCESSWIRE / April 21, 2023 / Alkermes plc (Nasdaq:ALKS) recently announced that the company will accept applications for its Alkermes Inspiration Grants® program beginning on May 1, 2023. Now in its seventh year, this competitive grant program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer.

"We see the gravity of unmet need in our communities to address stigmatized and increasingly complex health challenges - yet we remain hopeful because of the passion, energy and holistic problem-solving put forth by nonprofit organizations working on the front lines," said Richard Pops, Chief Executive Officer of Alkermes. "Through the Alkermes Inspiration Grants program, we have a unique opportunity to listen to, understand and empower organizations seeking to complement medicine and clinical care, and support populations who have faced longstanding and widespread health disparities."

This year's submissions will be evaluated based on the set of criteria outlined in the request for proposals, with a focus on people affected by alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, melanoma or ovarian cancer. Proposals should include clearly defined needs, objectives, activity format, mode of delivery and intended audience, and be relevant to historically under-resourced or underrepresented populations. Alkermes seeks to support programs that have a broad reach within the U.S. and potential to lead to sustained impact. Grant recipients will be selected by a committee that includes senior leaders from Alkermes and individuals from outside the company chosen to represent the perspectives of people with lived experience, caregivers and patient advocates.

Eligible U.S. 501(c)(3) nonprofit organizations may submit a grant application between May 1, 2023 and June 1, 2023. For more information on the Alkermes Inspiration Grants program, including submission instructions, additional eligibility guidelines, evaluation criteria and a link to the application portal, please visit https://www.alkermes.com/responsibility/alkermes-inspiration-grants-2023.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

ALKERMES INSPIRATION GRANTS® is a registered service mark of Alkermes, Inc.

Alkermes, Friday, April 21, 2023, Press release picture

View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com.

Contact Info:

Spokesperson: Alkermes
Website: https://www.3blmedia.com/profiles/alkermes
Email: info@3blmedia.com

SOURCE: Alkermes



View source version on accesswire.com:
https://www.accesswire.com/750643/Alkermes-Announces-Application-Period-for-2023-Alkermes-Inspiration-Grants-Program-To-Support-Innovative-Initiatives-Focused-on-People-Affected-by-Addiction-Serious-Mental-Illness-or-Cancer

FAQ

What is the Alkermes Inspiration Grants program?

The Alkermes Inspiration Grants program provides funding to nonprofit organizations that address the needs of individuals with addiction, mental illness, or cancer.

When can organizations apply for the Alkermes Inspiration Grants?

Organizations can submit applications from May 1, 2023, to June 1, 2023.

How much funding will be available through the Alkermes Inspiration Grants?

Up to $500,000 in total grants will be available for nonprofit organizations.

What eligibility criteria must organizations meet to apply for the grants?

Eligible organizations must be U.S. 501(c)(3) nonprofit entities and should address specific health issues affecting under-resourced populations.

What health issues are prioritized in the Alkermes Inspiration Grants program?

The program focuses on issues like alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, melanoma, and ovarian cancer.

Alkermes Inc. plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Stock Data

4.77B
169.22M
1.33%
113.13%
9.78%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DUBLIN 4